<DOC>
	<DOCNO>NCT02070835</DOCNO>
	<brief_summary>Diabetic foot ulcer one refractory wound always pose many challenge clinical practice . This study conduct prospective , randomise , control study compare safety efficacy ReCell® technology skin graft ( experiment group ) split-thickness skin graft ( STSG , control group ) alone treat diabetic foot ulcer .</brief_summary>
	<brief_title>Study ReCell® Treating Diabetic Foot Ulcers</brief_title>
	<detailed_description>The primary objective study ass effectiveness safety ReCell® skin graft ( experiment group ) vs. skin graft ( control group ) treatment non-healing diabetic foot ulcer . Our hypothesis method experiment group well control group .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Patients age 18 year old diagnosis type 1 type 2 diabetes diabetic low extremity ulcer last 4 week stage 2 Wagner 's scale size 3 cm2 absence vascular reconstruction ( ankle brachial index 0.7 1.2 ) indication skin graft eligible inclusion patient medical condition would impair wound healing ( e.g . malignancy , autoimmune disease ) , use corticosteroid immunosuppressor high anesthesiology surgical risk uncontrolled hyperglycemia ( preoperative HbA1c great 12.0 % )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Diabetic Foot Ulcer</keyword>
	<keyword>ReCell</keyword>
</DOC>